Every material Form 8-K Advanced Biomed Inc. has filed with the SEC since May 01, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Advanced Biomed Inc. gave notice on July 14, 2026 to terminate its June 6, 2025 purchase agreement with Helena Global Investment Opportunities I Ltd., which allowed the company to sell up to $25,000,000 of common stock to the investor at its discretion. The filing states no shares were sold under the agreement apart from commitment fee shares, and the termination takes effect July 21, 2026, so the company will no longer have this equity financing option.
Purchase agreement dated June 6, 2025 allowed sales of up to $25,000,000 of common stock to Helena Global Investment Opportunities I Ltd.
Termination notice delivered July 14, 2026 under Section 11.02(b), which requires five trading days' notice.
No advances were outstanding and all amounts owed, including commitment fee shares, were paid, per the filing.
Advanced Biomed Inc. agreed on June 30, 2026 to sell 100% of Advanced Biomed Inc. (Taiwan), its wholly-owned subsidiary that runs its biomedical research and development, to an unrelated third party. The filing says the company will keep its remaining businesses, including AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited, and the closing is expected within three months.
Aggregate purchase price is US$490,000, subject to the agreement's terms and conditions.
The Taiwan Subsidiary conducts the company's biomedical R&D, including the A+PerfusC 3D cell culture platform.
Closing is expected within three months of the agreement date; the filing lists closing conditions as a risk factor.
The full Share Purchase Agreement is filed as Exhibit 10.1.
Advanced Biomed completed its acquisition of 100% of Acellent Technologies (Hong Kong) Co. Limited on April 30, 2026, paying with 270,000 newly issued common shares valued at $4.00 each, or $1,080,000 in estimated consideration. The company also said it is pivoting from life sciences to artificial intelligence development, replacing CEO and Chairman Yi Lu with Xiaomin Chen, the seller of the acquired company, effective April 28, 2026.
Acquisition of Acellent Technologies (Hong Kong) completed April 30, 2026, for 270,000 shares valued at $4.00 per share, about $1,080,000 in estimated consideration
Yi Lu separated as CEO, director and Chairman under a mutual agreement; he will receive 39,999 shares as severance
Xiaomin Chen appointed CEO, director and Chairman effective April 28, 2026, and will receive $12,000 per month under his employment agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Advanced Biomed Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →